BEY2153

BEY2153 is an investigational small molecule drug developed by BeyondBio for the treatment of Alzheimer's disease. It acts as a dual inhibitor targeting both amyloid beta-protein and tau protein, which are implicated in the pathogenesis of Alzheimer's disease. By inhibiting these proteins, BEY2153 aims to reduce amyloid plaque formation and tau tangles in the brain—key pathological features associated with cognitive decline and neuronal death in Alzheimer's patients. Preclinical studies have shown that BEY2153 can enhance cognitive and behavioral functions while inhibiting neuronal death in animal models. The drug is designed for oral administration and demonstrates good blood-brain barrier permeability, potentially allowing efficacy at lower doses[2][4][5][7].